João Paulo Portela Catani

The breadth of protection mediated by anti-N2 neuraminidase antibody responses relies on cross-reactive and not cross-inhibiting antibodies

The study shows that cross-reactive antibodies, not cross-inhibiting ones, are responsible for broad protection against heterologous HxN2 influenza viruses.

Multi-segment mouse-adaptation of a recent B/Victoria-lineage virus independent from hemagglutinin and neuraminidase

This paper describes the generation of a mouse-adapted influenza B virus strain that gains pathogenicity in mice through mutations in non-HA/NA gene segments, independent of hemagglutinin and neuraminidase.

The antigenic landscape of N1 neuraminidase in human influenza A virus strains isolated between 2009 and 2020

The paper evaluates the antigenic evolution of N1 neuraminidase in H1N1 influenza viruses from 2009 to 2020, identifying key mutations driving antigenic changes and their impact on antibody neutralization.

Mosaic display of stable hemagglutinin monomers induces broad immune responses

This study develops a nanoparticle vaccine displaying conserved influenza HA epitopes, inducing broad neutralizing antibodies against multiple viral subtypes.

Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.